Login

Who is involved?

Home > General public > Who is involved?

The NOVELTY study combines the scientific and research expertise of AstraZeneca with that of leading global doctors and scientists in respiratory medicine. Alongside our scientific experts, people affected by asthma and/or chronic obstructive pulmonary disease (COPD) have made essential contributions to NOVELTY from the beginning.

Specific clinical practices, called study centres, from 19 countries around the world, are taking part. Click on each country to see how many patients are participating.

China

522

Scientific Committee

The Scientific Committee includes doctors from around the world who are experts in scientific topics that are important in NOVELTY, as well as team members from AstraZeneca.

Professor Helen Reddel
(Co-Chair)

Australia

Professor Helen Reddel
(Co-Chair)

Australia

Helen Reddel is Professor of Medicine at the Woolcock Institute of Medical Research, Australia. She is Chair of the Global Initiative for Asthma (GINA) Science Committee and member of the GINA Board of Directors and has led major changes in asthma guidelines.

Professor Reddel’s research focuses on management of chronic lung disease in primary care, collaborative approaches to improve patient care, prescribing and use of respiratory medicines, and population monitoring of chronic lung disease.

Professor Alberto Papi
(Co-Chair)

Italy

Professor Alberto Papi
(Co-Chair)

Italy

Alberto Papi is Professor of Respiratory Medicine at the University of Ferrara, Italy, and Director of the Respiratory Unit of the Department of Emergency Medicine, S. Anna University Hospital, Ferrara, Italy. He is also an Honorary Clinical Lecturer at the University of Southampton. He has previously served as a Member of the Asthma Board of the European Academy of Allergy and Clinical Immunology, and Secretary of the Respiratory Infections Group of the European Respiratory Society.

Professor Papi’s research primarily focuses on understanding the mechanisms and treatment of asthma and COPD; especially of airway inflammation, its molecular mechanisms and pharmacological modulation.

Professor Alvar Agustí

Spain

Professor Alvar Agustí

Spain

Alvar Agustí is Director of the Respiratory Institute at Hospital Clinic in Barcelona, and Professor of Medicine at the University of Barcelona. He is a member of the American Thoracic Society and European Respiratory Society (ERS; he has served as a member of the Executive Committee). Professor Agustí has a seat at the Royal Academy of Medicine of the Balearic Islands; he is also an Honorary Fellow of the Royal College of Physicians of Edinburgh, a Fellow of the ERS, and a member of the Scientific Committee and Board of Directors of the Global Initiative for Chronic Obstructive Lung Disease.

Professor Agustí’s main research interests include COPD and sleep disorders.

Professor Gary Anderson

Australia

Professor Gary Anderson

Australia

Gary Anderson is Professor and founding Director of the Lung Health Research Centre at the University of Melbourne, Victoria, Australia. He has served on the National Health and Medical Research Council (NHMRC) Research Committee, and on the Board of Directors of the Thoracic Society of Australia and New Zealand (TSANZ) as Chair of the Research Committee. He also serves on the Council of the Australian Lung Foundation.

Professor Anderson’s research focuses on genetic disease models and clinical cohorts to understand molecular mechanisms of asthma and COPD. In 2008, he proposed the widely adopted ‘endotype’ concept in asthma.

Dr Aruna Bansal

UK

Dr Aruna Bansal

UK

Aruna Bansal is Biostatistician and Founder of Acclarogen Ltd., a consultancy company supporting the pharmaceutical and life science sectors, based in Cambridge, UK. Dr Bansal is providing expertise for the statistical analyses of the NOVELTY study.

Prior to founding Acclarogen, Dr Bansal was Assistant Professor at the University of Utah, and Director and Worldwide Head of Genetic Analysis at GlaxoSmithKline. She has also been appointed Chief Statistician of U-BIOPRED, a Europe-wide 5-year project studying severe asthma.

Professor Richard Beasley

New Zealand

Professor Richard Beasley

New Zealand

Richard Beasley is a physician at Wellington Regional Hospital, New Zealand, and Director of the Medical Research Institute of New Zealand, and Deputy Chair of the Health Research Council of New Zealand. He is an Adjunct Professor at the University of Otago and Victoria University of Wellington, and Visiting Professor at the University of Southampton, UK.

Professor Beasley’s research interests in respiratory medicine are primarily in the fields of epidemiology and clinical management.

Professor Elisabeth Bel

The Netherlands

Professor Elisabeth Bel

The Netherlands

Elisabeth Bel is Professor of Pulmonary Diseases at Amsterdam UMC, University of Amsterdam, The Netherlands. She is a past President of the European Respiratory Society (ERS) and has been a member of the ERS Board and Scientific Committee since 2002.

Professor Bel’s research interests focus on difficult-to-treat, severe types of asthma.

Professor J. Mark FitzGerald

Canada

Professor J. Mark FitzGerald

Canada

J. Mark FitzGerald is Director of the Centre for Heart and Lung Health at the Vancouver Coastal Health Research Institute and Co-Director of the University of British Columbia (UBC) Institute for Heart and Lung Health. He is also a respiratory physician at The Lung Centre, Vancouver General Hospital, and a former Head of the Respiratory Medicine Divisions at the UBC and Vancouver General Hospital.

Professor FitzGerald is a past President of the Canadian Thoracic Society (CTS) and a past Chair and current member of the Global Initiative for Asthma (GINA) Science Committee, the GINA Executive and the CTS Asthma Assembly.

Professor Christer Janson

Sweden

Professor Christer Janson

Sweden

Christer Janson is Professor at the Department of Medical Sciences: Respiratory, Allergy and Sleep Research at Uppsala University, Sweden. He is Secretary of the Assembly on Occupation and Epidemiology at the European Respiratory Society, a member of the Steering Committee of the European Community Respiratory Health Survey II and III, and Project Leader of the Respiratory Health in Northern Europe study.

Professor Janson’s research interests include COPD, asthma and allergy epidemiology, inflammation in these diseases, and sleep-disordered breathing.

Professor Barry Make

USA

Professor Barry Make

USA

Barry Make is Co-Director of the COPD Program and Director of Pulmonology Rehabilitation and Respiratory Care at National Jewish Health in Denver, Colorado, USA. He is also Professor of Medicine in the Division of Pulmonary Sciences and Critical Care Medicine at the University of Colorado Denver. Professor Make is a Fellow of the American College of Chest Physicians and the American Association of Cardiovascular and Pulmonary Rehabilitation.

Professor Make’s primary clinical research interest is on the management and outcomes of COPD; he has been recognised as one of the Castle Connolly’s Top Doctors in The US for the past 10 years.

Professor Richard Martin

USA

Professor Richard Martin

USA

Richard Martin is Chairman of the Department of Medicine at National Jewish Health, and Professor of Medicine at National Jewish Health and the University of Colorado Denver, USA. He holds the Edelstein Chair in Pulmonary Medicine, and is the recipient of the American College of Chest Physicians Distinguished Scholar Award in Respiratory Health.

Professor Martin’s research interests are in adult asthma, including airways inflammation, refractory asthma, nocturnal asthma and the interaction of chronic infections with asthma and COPD.

Professor Ian Pavord

UK

Professor Ian Pavord

UK

Ian Pavord is Professor of Respiratory Medicine at the University of Oxford and Honorary Consultant Physician at the Oxford University Hospitals. He is a Fellow of the European Respiratory Society and of the Academy of Medical Science.

Professor Pavord focuses on the clinical aspects of inflammatory airways disease and non-invasive measures of airways inflammation. He has identified several clinically important phenotypes of inflammatory airways disease and has played a lead role in developing new treatments for severe airways disease.

Professor David Price

Singapore and UK

Professor David Price

Singapore and UK

David Price is Managing Director of the Observational and Pragmatic Research Institute (a company focused on observational research and real-world evidence), Singapore, and Primary Care Respiratory Society Professor of Primary Care Respiratory Medicine at the University of Aberdeen, UK. He is a past Chair of the research committee of the International Primary Care Respiratory Group and is a member of the executive committee for the international ARIA and EPOS guidelines groups.

Professor Price is extensively involved in respiratory and allergy research, especially ‘real-life’ effectiveness and cost-effectiveness of interventions, clinical trial design, compliance and patient attitudes to their disease.

Professor Mohsen Sadatsafavi

Canada

Professor Mohsen Sadatsafavi

Canada

Mohsen Sadatsafavi is Associate Professor of Health Outcomes at the University of British Columbia and Associate Director of Research at Collaboration for Outcomes Research and Evaluation.

Professor Sadatsafavi leads the Respiratory Evaluation Sciences Program, a laboratory that is specialised in predictive analytics in asthma and COPD. He has received numerous awards for his work, including the New Investigator Award from the Canadian Institutes of Health Research (CIHR) and the Michael Smith Foundation for Health Research.

Professor Jørgen Vestbo

UK

Professor Jørgen Vestbo

UK

Jørgen Vestbo is Professor of Respiratory Medicine at the University of Manchester, UK, and Honorary Consultant at the North West Lung Centre, Manchester. He is President of the European Respiratory Society, and has been influential in developing international guidelines for COPD diagnosis and management.

Professor Vestbo’s research interests are on clinical epidemiology and management of COPD, and the impact of treatment on the natural history of COPD.

Dr Hana Müllerová
(AstraZeneca Co-Chair)

AstraZeneca, UK

Dr Hana Müllerová
(AstraZeneca Co-Chair)

AstraZeneca, UK

Hana Müllerová is an industry Epidemiologist currently leading a COPD medical evidence group at AstraZeneca, UK. Dr Müllerová has been involved in researching respiratory diseases such as asthma and COPD for nearly 20 years. Her research interests include exacerbations, comorbidities and risk-benefit assessments for new and existing medications for these diseases.

Dr Rod Hughes

AstraZeneca, UK

Dr Rod Hughes

AstraZeneca, UK

Rod Hughes is a trained Respiratory Physician. He worked in the UK National Health Service (NHS) until joining AstraZeneca, UK, in 2017. Dr Hughes’ research interests focus on improving care pathways and assessing novel treatment approaches for patients hospitalised with asthma and COPD. Since joining AstraZeneca, he has worked with clinicians across the world to improve awareness of appropriate assessment and medication use in patients with respiratory diseases.

Dr Sarowar Muhammad Golam

AstraZeneca, Sweden

Dr Sarowar Muhammad Golam

AstraZeneca, Sweden

Sarowar Golam is a Health Economist at AstraZeneca, Sweden and a trained physician. He has worked in the field of respiratory disease for almost 10 years. He has significant experience in the research and development of biologics and inhaled medications for asthma and COPD. Before working for AstraZeneca, he worked at the Karolinska Institute, Sweden, and at the University of York, UK, as a research fellow.

Erin Tomaszewski

AstraZeneca, USA

Erin Tomaszewski

AstraZeneca, USA

Erin Tomaszewski works in Patient-centred Science, AstraZeneca, UK. She has 13 years of experience primarily dedicated to research on patient-reported outcomes (PROs) and the patient experience. She has been involved in regulatory strategy planning and PRO development and implementation. She is also involved in PRO instrument ownership, licensing and distribution; training and management of PRO teams; writing manuscripts and abstracts and implementation of digital solutions capturing the patient experience.

Patient advocates

NOVELTY was designed with the help of a patient partnership programme, which means that people affected by asthma and/or COPD have been bringing their experiences to the study from the beginning. We would like to thank these patient advocates for their time and commitment to building a better study design and for helping us to share the information that matters to the patient community in the right way. If you are interested in getting involved in the AstraZeneca patient partnership programme, please visit: https://www.AZpatientpartners.com/

19 PARTICIPATING COUNTRIESa
~12,000 ENROLLED PATIENTSa
80% OF PATIENTS HAVE SPIROMETRY DATAb

You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study